SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. For the third quarter of 2020, revenue was $31.1 million, compared to $20.7 million in the second quarter of 2020 and $31.0 million in the third quarter of 2019. Product and testing revenue was $30.3 million, an increase of 79% over the second quarter of 2020 and 13% over the third quarter of 2019.
“We are pleased with the strong rebound in our business during the third quarter, with revenue returning to pre-pandemic levels, led by our Afirma franchise,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “We also achieved important reimbursement and clinical-evidence milestones for our tests, which we believe will help further drive adoption and revenue growth. We also remain on track to launch four new clinical products in 2021. Moreover, we believe we are well-positioned in the near- and long-term with our tests that help patients avoid unnecessary invasive diagnostic procedures and accelerate access to appropriate treatment.”
Third Quarter 2020 Financial Results
For the third quarter of 2020:
- Total Revenue was $31.1 million, comprising $30.3 million in testing and product revenue and $0.8 million in biopharmaceutical partnership revenue;
- Gross Margin was 67%;
- Operating Expenses, Excluding Cost of Revenue, were $24.8 million;
- Net Loss and Comprehensive Loss was $4.1 million;
- Basic and Diluted Net Loss Per Common Share was $0.08;
- Net Cash Provided by Operating Activities was $1.8 million; and
- Cash and Cash Equivalents were $345.1 million at September 30, 2020.
For the nine-month period ended September 30, 2020:
- Total revenue was $82.9 million, comprising $77.6 million in testing and product revenue and $5.3 million in biopharmaceutical partnership revenue;
- Gross Margin was 64%;
- Operating Expenses, Excluding Cost of Revenue were $80.0 million;
- Net Loss and Comprehensive Loss was $26.9 million;
- Basic and Diluted Net Loss Per Common Share was $0.52; and
- Net Cash Used in Operating Activities was $12.0 million.
Third Quarter 2020 and Recent Business Highlights
Commercial Growth and Reimbursement Expansion:
- Grew reported genomic testing volume (Afirma, Percepta and Envisia) to 10,242, an increase of 90% over the second quarter of 2020 and 3% over the third quarter of 2019.
- Generated $7.0 million in year-to-date 2020 revenue from our Prosigna breast cancer test, achieving our pre-pandemic, full-year 2020 revenue goal.
- Received Advanced Diagnostic Laboratory Test (ADLT) status and new Medicare pricing for the Envisia classifier, beginning October 1, 2020, positioning the test for expanded revenue growth.
- Received new CPT codes and preliminary national Medicare pricing for the Afirma Medullary Thyroid Carcinoma (MTC) classifier and the Xpression Atlas, providing a pathway for increased reimbursement.
- Obtained coverage for the Prosigna breast cancer test from the Federal Joint Committee (G-BA) in Germany, our third largest European market.
Evidence Development:
- Prosigna:
- Launched the PROCURE study, led by a distinguished, independent scientific committee of breast cancer experts and including input from 180 clinicians throughout Europe, intended to achieve consensus on the evidence supporting the most frequently used breast cancer genomic tests, including Prosigna.
- Data from the TransATAC study were published in the Journal of Clinical Oncology elucidating the foundational molecular biology on which the Prosigna test is based and its higher likelihood of predicting long-term risk of recurrence among certain groups of women with early-stage breast cancer, compared to other breast cancer genomic tests.
- Afirma:
- An independent study published in Cytopathology by UCLA researchers showed that use of the Afirma GSC further reduced unnecessary surgeries in thyroid cancer diagnosis compared to the original Afirma test.
- Pulmonology:
- Presented three e-Posters at the American Thoracic Society 2020 Virtual Meeting featuring real-world data that reinforce previous findings suggesting that the Percepta and Envisia classifiers improve the diagnosis of lung cancer and interstitial lung diseases (ILDs).
- Published data in the journal CHEST suggesting that the Percepta classifier reduces unnecessary invasive procedures following inconclusive bronchoscopy results for patients with lung nodules and that these results are durable for over one year of follow-up.
- Presented an oral and e-Poster presentation at CHEST Annual Meeting 2020 supporting advancement of our lung cancer nasal swab classifier, along with the potential to integrate radiologic data to further augment genomics in the diagnosis of ILDs, including idiopathic pulmonary fibrosis.
Financing:
- Issued and sold 6,900,000 shares of common stock in August 2020 in a registered public offering, including the underwriters’ exercise in full of their option to purchase an additional 900,000 shares, at a price to the public of $30.00 per share. Net proceeds from the offering were approximately $194 million.
2020 Financial Guidance
While Veracyte experienced improved business trends in the third quarter, due to the continued uncertainties with respect to the COVID-19 pandemic, the company will not be providing guidance at this time.
Conference Call and Webcast Details
Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/rxzuzy8m. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.
The conference call can be accessed as follows:
U.S./Canada participant dial-in number (toll-free): |
(855) 541-0980 |
|
International participant dial-in number: |
(970) 315-0440 |
|
Conference I.D.: |
3190445 |
About Veracyte
Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, and nasal swab tests and products for use in diagnosing and treating diseases. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: Veracyte’s ability to achieve and maintain Medicare coverage for its tests; the benefits of Veracyte’s tests, the applicability of clinical results to actual outcomes and the effects of the COVID-19 pandemic on Veracyte’s business and performance. Factors that may impact these forward-looking statements can be found in Item 1A – “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 25, 2020 and in our Quarterly Report on Form 10-Q to be filed with the SEC on November 2, 2020. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, Afirma, Percepta, Envisia, Prosigna, "Know by Design" and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are registered trademarks in the U.S. and selected countries. We have common law rights and pending trademark applications for LymphMark and “More About You.”
| VERACYTE, INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands of dollars, except share and per share amounts) | ||||||||||||||||
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Revenue: | ||||||||||||||||
| Testing revenue | $ |
28,270 |
|
$ |
26,723 |
|
$ |
70,473 |
|
$ |
78,798 |
|
||||
| Product revenue |
|
2,027 |
|
|
— |
|
|
7,149 |
|
|
— |
|
||||
| Biopharmaceutical revenue |
|
824 |
|
|
2,250 |
|
|
5,325 |
|
|
7,840 |
|
||||
| Collaboration revenue |
|
— |
|
|
2,000 |
|
|
— |
|
|
4,000 |
|
||||
| Total Revenue |
|
31,121 |
|
|
30,973 |
|
|
82,947 |
|
|
90,638 |
|
||||
| Operating expenses: | ||||||||||||||||
| Cost of testing revenue |
|
9,118 |
|
|
9,114 |
|
|
26,157 |
|
|
26,404 |
|
||||
| Cost of product revenue |
|
1,048 |
|
|
— |
|
|
3,539 |
|
|
— |
|
||||
| Cost of biopharmaceutical revenue |
|
204 |
|
|
— |
|
|
572 |
|
|
— |
|
||||
| Research and development |
|
4,042 |
|
|
3,643 |
|
|
12,618 |
|
|
10,408 |
|
||||
| Selling and marketing |
|
10,955 |
|
|
13,088 |
|
|
39,240 |
|
|
39,508 |
|
||||
| General and administrative |
|
8,546 |
|
|
6,624 |
|
|
24,316 |
|
|
20,448 |
|
||||
| Intangible asset amortization |
|
1,274 |
|
|
267 |
|
|
3,822 |
|
|
800 |
|
||||
| Total operating expenses |
|
35,187 |
|
|
32,736 |
|
|
110,264 |
|
|
97,568 |
|
||||
| Loss from operations |
|
(4,066 |
) |
|
(1,763 |
) |
|
(27,317 |
) |
|
(6,930 |
) |
||||
| Interest expense |
|
(55 |
) |
|
(58 |
) |
|
(175 |
) |
|
(596 |
) |
||||
| Other income (loss), net |
|
(3 |
) |
|
1,091 |
|
|
627 |
|
|
2,385 |
|
||||
| Net loss and comprehensive loss | $ |
(4,124 |
) |
$ |
(730 |
) |
$ |
(26,865 |
) |
$ |
(5,141 |
) |
||||
| Net loss per common share, basic and diluted | $ |
(0.08 |
) |
$ |
(0.02 |
) |
$ |
(0.52 |
) |
$ |
(0.11 |
) |
||||
| Shares used to compute net loss per common share, basic and diluted |
|
54,858,052 |
|
|
48,588,296 |
|
51,632,750 |
|
45,141,502 |
|||||||
| VERACYTE, INC. | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (In thousands) | ||||||
| September 30, 2020 |
December 31, 2019 |
|||||
| (Unaudited) | (See Note 1) | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ |
345,080 |
$ |
159,317 |
||
| Accounts receivable |
|
17,629 |
|
19,329 |
||
| Supplies |
|
4,456 |
|
6,806 |
||
| Prepaid expenses and other current assets |
|
3,150 |
|
2,235 |
||
| Total current assets |
|
370,315 |
|
187,687 |
||
| Property and equipment, net |
|
8,914 |
|
8,933 |
||
| Right-of-use assets - operating lease |
|
8,094 |
|
8,808 |
||
| Finite-lived intangible assets, net |
|
61,197 |
|
65,019 |
||
| Goodwill |
|
2,725 |
|
2,725 |
||
| Restricted cash |
|
603 |
|
603 |
||
| Other assets |
|
2,303 |
|
1,437 |
||
| Total assets | $ |
454,151 |
$ |
275,212 |
||
| Liabilities and Stockholders’ Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ |
1,932 |
$ |
2,328 |
||
| Accrued liabilities |
|
10,445 |
|
13,734 |
||
| Current portion of operating lease liability |
|
1,542 |
|
1,407 |
||
| Total current liabilities |
|
13,919 |
|
17,469 |
||
| Long-term debt |
|
756 |
|
694 |
||
| Acquisition-related contingent consideration |
|
6,420 |
|
6,088 |
||
| Operating lease liability, net of current portion |
|
10,331 |
|
11,506 |
||
| Total liabilities |
|
31,426 |
|
35,757 |
||
| Total stockholders’ equity |
|
422,725 |
|
239,455 |
||
| Total liabilities and stockholders’ equity | $ |
454,151 |
$ |
275,212 |
||
(1) The condensed balance sheet at December 31, 2019 has been derived from the audited financial statements at that date included in the Company's Form 10-K filed with the Securities and Exchange Commission dated February 25, 2020.
| VERACYTE, INC. | ||||||||
| CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS | ||||||||
| (Unaudited) | ||||||||
| (in thousands of dollars) | ||||||||
Nine Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
| Operating activities | ||||||||
| Net loss | $ |
(26,865 |
) |
$ |
(5,141 |
) |
||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization |
|
5,919 |
|
|
2,836 |
|
||
| Gain on disposal of property and equipment |
|
— |
|
|
(23 |
) |
||
| Stock-based compensation |
|
9,354 |
|
|
6,965 |
|
||
| Amortization of debt issuance costs |
|
— |
|
|
83 |
|
||
| Interest on end-of-term debt obligation |
|
162 |
|
|
174 |
|
||
| Write-down of excess supplies |
|
1,088 |
|
|
— |
|
||
| Noncash lease expense |
|
714 |
|
|
810 |
|
||
| Revaluation of acquisition-related contingent consideration |
|
332 |
|
|
— |
|
||
| Effect of foreign currency on operations |
|
(17 |
) |
|
— |
|
||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable |
|
1,742 |
|
|
(10,445 |
) |
||
| Supplies |
|
1,262 |
|
|
(3,206 |
) |
||
| Prepaid expenses and other current assets |
|
(923 |
) |
|
185 |
|
||
| Other assets |
|
134 |
|
|
(142 |
) |
||
| Operating lease liability |
|
(1,040 |
) |
|
(881 |
) |
||
| Accounts payable |
|
(534 |
) |
|
2,505 |
|
||
| Accrued liabilities |
|
(3,300 |
) |
|
1,258 |
|
||
| Net cash used in operating activities |
|
(11,972 |
) |
|
(5,022 |
) |
||
| Investing activities | ||||||||
| Purchases of property and equipment |
|
(1,949 |
) |
|
(1,656 |
) |
||
| Purchase of equity securities |
|
(1,000 |
) |
|
— |
|
||
| Proceeds from disposal of property and equipment |
|
— |
|
|
23 |
|
||
| Net cash used in investing activities |
|
(2,949 |
) |
|
(1,633 |
) |
||
| Financing activities | ||||||||
| Proceeds from the issuance of common stock in a public offering, net |
|
193,831 |
|
|
137,848 |
|
||
| Payment of long-term debt |
|
(100 |
) |
|
(24,900 |
) |
||
| Payment of finance lease liability |
|
— |
|
|
(229 |
) |
||
| Payment of taxes on vested restricted stock units |
|
(3,161 |
) |
|
(810 |
) |
||
| Proceeds from the exercise of common stock options and employee stock purchases |
|
10,114 |
|
|
12,413 |
|
||
| Net cash provided by financing activities |
|
200,684 |
|
|
124,322 |
|
||
| Net increase in cash, cash equivalents and restricted cash |
|
185,763 |
|
|
117,667 |
|
||
| Cash, cash equivalents and restricted cash at beginning of period |
|
159,920 |
|
|
78,598 |
|
||
| Cash, cash equivalents and restricted cash at end of period | $ |
345,683 |
|
$ |
196,265 |
|
||
| Supplementary cash flow information: | ||||||||
| Purchases of property and equipment included in accounts payable and accrued liability | $ |
355 |
|
$ |
821 |
|
||
| Interest paid on debt | $ |
3 |
|
$ |
330 |
|
||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH | ||||||
| (Unaudited) | ||||||
| (In thousands of dollars) | ||||||
| September 30, 2020 | December 31, 2019 | |||||
| Cash and cash equivalents | $ |
345,080 |
$ |
159,317 |
||
| Restricted cash |
|
603 |
|
603 |
||
| Total cash, cash equivalents and restricted cash | $ |
345,683 |
$ |
159,920 |
||
